Umeclidinium bromide/vilanterol

Umeclidinium bromide/vilanterol
Umeclidinium bromide (TOP), vilanterol (BOTTOM)
Combination of
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Names
Trade namesAnoro Ellipta, Laventair Ellipta
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
    Routes of
    use    		Inhalation (DPI)
    External links
    AHFS/Drugs.comProfessional Drug Facts
    Legal
    License data
    Legal status

    Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).[3][4] It is applied as an inhalation.

    The most common side effects include upper respiratory tract infections (nose and throat infection), urinary tract infections (infection of the structures that carry urine), pharyngitis (inflammation of the throat), sinusitis (inflammation of the sinuses), nasopharyngitis (inflammation of the nose and throat), headache, cough, oropharyngeal pain (pain in the mouth and throat), constipation and dry mouth.[2]

    Society and culture

    Cost

    The cost of 60 blisters of 62.5 mg umeclidinium/25 mcg vilanterol in this medication is $425 to $500 (USD) for one inhaler [5]

    • Umeclidinium bromide/vilanterol costs (US)
      Umeclidinium bromide/vilanterol costs (US)
    • Umeclidinium bromide/vilanterol prescriptions (US)
      Umeclidinium bromide/vilanterol prescriptions (US)

    References

    1. ↑ "Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Archived from the original on 29 August 2021. Retrieved 29 October 2020.
    2. 1 2 "Anoro Ellipta EPAR". European Medicines Agency (EMA). Archived from the original on 11 November 2020. Retrieved 28 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
    3. ↑ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282. Archived from the original on 2021-08-29. Retrieved 2020-02-02.
    4. ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013. Archived from the original on September 24, 2017. Retrieved January 13, 2014.
    5. ↑ "How much does Anoro Ellipta cost without insurance?". Drugs.com. Archived from the original on 29 August 2021. Retrieved 9 April 2021.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.